GeneThera (GeneThera) EV-to-EBIT : -1.54 (As of Apr. 25, 2024)

GeneThera EV-to-EBIT Chart

GeneThera Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBIT		Get a 7-Day Free Trial					-2.55	-0.49	-2.46	-1.59	-1.92

GeneThera Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EV-to-EBIT	Get a 7-Day Free Trial															-2.98	-1.92	-2.28	-2.00	-2.04

Competitive Comparison of GeneThera's EV-to-EBIT

For the Biotechnology subindustry, GeneThera's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneThera's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GeneThera's EV-to-EBIT falls into.

GeneThera EV-to-EBIT Calculation

GeneThera's EV-to-EBIT for today is calculated as:

GeneThera's current Enterprise Value is $1.05 Mil.
GeneThera's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneThera  (OTCPK:GTHR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

GeneThera's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

GeneThera's Enterprise Value for the quarter that ended in Sep. 2022 was $1.39 Mil.
GeneThera's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneThera EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of GeneThera's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneThera (GeneThera) Business Description